TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sustained increase in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measurable residual disease (MRD) undetectable complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory response measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to LUS Scan Protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Accurate LUS Data Collection for Comparison with Chest X-rays
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global Longitudinal Strain (GLS) of the left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Response Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Objective Response (OR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rates of grade 2/3 adverse events and symptom reactivity following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of immunogenicity following vaccination (Cohort I)
Endpoint domain: Physiological/clinical
Primary endpoint: Rate of immunogenicity following revaccination (Cohort II)
Endpoint domain: Physiological/clinical
Primary endpoint: overall recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: participant satisfaction surveys
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants Achieving a ≥50% Decrease in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clotting score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute change in peak intraepithelial mast cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerance to nutritional therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain 24 hours post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ-support-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in haptoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in potassium (K+) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in creatine kinase (CK) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum myoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine myoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in information processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ventricular epicardial adipose tissue (EAT) mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimated extracellular volume (eECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPMN Progression Free Survival (iPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Decline in log quantitative HBsAg level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of households with SARS-CoV-2 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of USD-ETTs visualized by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful seizure induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: working memory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC Screening Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adults screened for substance use disorder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of adults screened for substance use disorder
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correct Condom Use Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexual and reproductive care receipt
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Simulated Energy Intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-month relapse events
Endpoint domain: Mortality/survival
Primary endpoint: cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suvorexant effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary artery Pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient's global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Generalized Anxiety Disorder Questionnaire (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Beck Anxiety Inventory (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Beck Depression Inventory (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants developing a RVI
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change from baseline in muscle mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in grip strength (kgf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in bone mineral density (BMD) (g/cm²)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of mobile application
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Usability of mobile application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of mobile application
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-surgical recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with increased tumor RAI-avidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic performance of AI-ECG for left ventricular ejection fraction (LVEF) < 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of AI-ECG and NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intraoperative haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of LY3537982 monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of LY3537982
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor activity of LY3537982 monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relapse of VAD-infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with local and systemic reactogenicity adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Device Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Homocysteine in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of Ferritin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of Sit-to-stand for strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallstone detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tdap vaccination rate for non-birthing partners
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major pathologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using Numeric Rating Scale-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient and physician satisfaction assessed by 5-point Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants who score a 39 or higher using the OM perceived value survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of recovery (QoR-15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of sample that is abstinent from alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum or plasma GLP-1 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum or plasma GIP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum or plasma ghrelin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum or plasma c-peptide changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum or plasma insulin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum or plasma glucagon changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Patients with Criminal justice system involvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients with Adverse Social Determinants of Health
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients reporting favorable outcomes of Violence Intervention Services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of revealing patients carrying genotype associated with a monogenic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV reactivity during stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of the 5-HT4 receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in Nonalcoholic fatty liver disease activity score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rotation deviation of the trunk at the level of L3 vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoliotic angle in sweep rowers during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk deviation in the frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of scoliotic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Response Rate (RRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Fibromyalgia Impact Questionnaire-Revised (FIQR) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric mean titers of anti HPV 16 and 18 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Multidimensional fatigue Inventory-20
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quit smoking motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients prescribed SGLT2i
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of participants eligible, enrolled and retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: axillary recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy assessed by response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical efficiency of NOSE procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and Severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in gut metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in gut metabolite production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Density Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular responses in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemogram levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Shock indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRI healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year change in global cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Tower of Hanoi task (TOH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Task Switching Paradigm (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Colour Trails Test-2 (CTT-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Maintenance of Body Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Telehealth Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Telehealth Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in the total score MDS-UPDRS Part II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of any grade cytokine release syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive scaled score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ETV/CPC treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase II dose (RP2D)
Endpoint domain: Resource use
Primary endpoint: Percentage of Participants Who Complete 100% of the Outcome Assessments at Study Conclusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Report Scores ≥4 for Their Final Rating of the Intervention's Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Report Scores ≥4 for Their Final Rating of the Intervention's Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete or near complete resolution of organ involvement at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or near complete resolution of erythema at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete or near complete resolution of erythema at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Breathlessness, Cough and Sputum Scale (BCSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Combined Statistical Test (CST) for ADCS-ADL and Mini-Mental State Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of participants with salt sensitive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adhesion to an APA program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of participants who attend intervention sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Achieving Responder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Incidence of All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in the proportion of embedded clinic patients with an HbA1c >9%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: test performance on the LQYBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of severe pain syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of manipulation under anesthesia (MUA) after elective total knee arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Binocular visual acuity at distance (4 meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait complexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current Opioid Misuse Measure (COMM) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oxygenated hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deoxygenated hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Bayley Scales of Infant and Toddler Development (Bayley-3) More Affected Arm Motor Function Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parenting Styles and Dimensions Questionnaire (PSDQ) Authoritative Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of advance directive (AD) completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of documented conversations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct inpatient cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinically significant reduction in net fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from mortality or heart failure re-hospitalization/therapy escalation
Endpoint domain: Mortality/survival
Primary endpoint: Improved GLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test result concordance between lay users and professional users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Test result concordance between lay users and laboratory results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Examiner Rater-Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional Pathology of the Musculoskeletal System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: National Institutes of Health Neuro-Quality of Life (QoL) survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Oral Health Related Quality of Life and Patient Satisfaction After Surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systolic blood pressure response to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term overall remission rate
Endpoint domain: Mortality/survival
Primary endpoint: Recording of deep sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Recording of light sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Recording of REM sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep